China: New Covid-19 Vaccine Induces Rapid Immune Response

FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo


China: New Covid-19 Vaccine Induces Rapid Immune Response

The new drug is considered the first candidate for the COVID-19 vaccine today.

The Chinese drug manufacturer CanSino Biologics, from the city of Wuhan, developed a vaccine against Covid-19 that has been found to be safe and induces a rapid immune response.

The Lancet released the data from the phase one trial, and considers it the first candidate for the COVID-19 vaccine today.

The findings were released Friday, days after an American biotechnology company announced that it had also developed a vaccine that has proven safe and capable of stimulating an immune response in the human body against the virus.

The drug, developed by Modern biotech, has been challenged, however, after the company failed to share data from its phase one trials.

The drug is known as Covid-19 vaccine vectored by recombinant adenovirus type 5 (AD5), and was tested in 108 healthy adults living in Wuhan who are between 18 and 60 years old.

The researchers tested the volunteers’ blood at regular intervals after they were vaccinated.

They sought to prove that the vaccine stimulated the immune system to produce neutralizing antibodies, which can fight infection and may provide a level of immunity.

They also sought to stimulate the cells of the body, which relies on a group of T cells, rather than antibodies, to fight the virus.

Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy